Prefer to listen without the ads? Become a Ben Bikman Insider.
Weight loss medications are evolving quickly.
For years, metabolic medicine focused on one primary hormonal pathway at a time. First came GLP-1 receptor agonists like semaglutide. Then dual agonists like tirzepatide entered the picture by combining GLP-1 and GIP signaling. Now, a new class of medication is emerging that may represent the next major step in obesity and metabolic treatment: retatrutide.
What makes retatrutide unique is not simply the amount of weight loss seen in clinical trials — though those results are certainly noteworthy. What makes this drug scientifically interesting is the addition of a third hormonal pathway: glucagon.
In this week’s Metabolic Classroom, I explain why glucagon may be the key ingredient that changes the conversation.
From Single Hormones to Triple Agonists
To understand retatrutide, it helps to understand the progression of these medications.
Early drugs in this category primarily activated one receptor:
- GLP-1 medications helped reduce appetite and slow gastric emptying.
- Tirzepatide expanded the approach by activating both GLP-1 and GIP receptors.
Retatrutide takes things one step further.
Rather than activating one or two metabolic pathways, it activates three:
- GLP-1
- GIP
- Glucagon
Each contributes something different to metabolism, but the glucagon receptor is what gives retatrutide its unique profile.
What GLP-1 and GIP Already Do
The GLP-1 pathway is the most familiar.
This signaling helps reduce hunger, slow digestion, and improve post-meal glucose control. It largely works by decreasing how much someone wants to eat.
GIP appears to amplify many of these benefits. It may improve appetite regulation while also helping reduce some of the gastrointestinal side effects commonly associated with higher-dose GLP-1 medications.
Together, GLP-1 and GIP primarily influence the input side of energy balance — in other words, how much fuel enters the body.
But metabolism is about more than food intake.
Why Glucagon Changes the Equation
Glucagon works on the output side of metabolism.
Instead of simply reducing appetite, glucagon signaling appears to increase how much energy the body uses.
This includes:
- Increased fat oxidation
- Higher energy expenditure
- Improved fat clearance from the liver
- Greater metabolic activity through what researchers call “futile cycling”
In simple terms, glucagon helps the body burn more energy.
The liver appears to be the primary target.
When glucagon binds to receptors in the liver, it promotes fat burning, reduces fat creation, and may help clear excess fat stored in tissues such as the liver itself. This is one reason retatrutide has shown particularly impressive early results for fatty liver disease.
Clinical studies have shown dramatic reductions in liver fat among participants taking retatrutide, with many returning to normal liver fat levels during treatment.
Fat Loss Without Direct Muscle Breakdown?
One of the most interesting aspects of retatrutide is what glucagon doesn’t target.
Skeletal muscle does not appear to express functional glucagon receptors.
That means glucagon’s metabolic signaling is directed primarily toward the liver and fat tissue — not muscle tissue.
This distinction matters.
One of the biggest concerns with aggressive weight loss is preserving lean mass. While no medication completely eliminates that concern, retatrutide’s mechanism suggests it may help drive fat loss without direct glucagon-related catabolic signaling occurring in muscle.
In short:
Fat responds. The liver responds. Muscle largely ignores the glucagon signal.
What the Clinical Trials Show
The early human data are impressive.
In obesity trials, participants lost nearly 29% of body weight at the highest doses studied.
Retatrutide has also demonstrated improvements in:
- Blood sugar regulation
- Liver fat reduction
- Triglycerides
- Inflammation markers
- Blood pressure
While additional research is still underway, these results suggest retatrutide may become one of the most powerful metabolic therapies currently in development.
The Bigger Lesson: Medication as a Bridge
As promising as these medications are, there is an important principle worth remembering.
Drugs like retatrutide work best when they become a bridge, not a permanent replacement for lifestyle change.
If appetite is reduced and cravings quiet down, that creates an opportunity — a period of time to relearn how to eat, improve metabolic flexibility, reduce dependence on processed carbohydrates, and build sustainable habits.
The goal should not simply be weight loss.
The goal is metabolic health.
The best-case scenario is using the tool to help restore metabolic function while gradually becoming less dependent on the tool itself.
Final Thoughts
Retatrutide represents the next logical evolution in metabolic medicine.
By combining GLP-1, GIP, and glucagon signaling into one therapy, it may address both sides of energy balance: helping people eat less while simultaneously increasing energy expenditure.
And while the headlines will focus on weight-loss percentages, the more interesting story may be what glucagon is doing behind the scenes.
If you want to better understand the science of metabolism and how these therapies actually work, watch the full Metabolic Classroom episode above.